Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC

touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients. Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Prof. Nicholas Girard, Institut Curie, Paris, France   Module 2: Bridging resistance gaps post–EGFR-TKI: Expanding NSCLC treatment beyond actionable targets In this module, Professor Pasi Jänne and Dr. Helena Yu discuss the evolving management of EGFR-mutant NSCLC after EGFR-TKI progression. They address challenges of unexplained resistance, review combination and ADC treatment approaches, and highlight key factors such as patient selection, safety and emerging biomarkers Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Dr Helena Yu, Memorial Sloan Kettering Cancer Center, New York, NY, USA   Module 3: Targeting resistance in EGFR-mutant NSCLC: The role of biomarkers In this module, Professor Pasi Jänne and Professor Paul Hofman explore how precision medicine and molecular resistance mechanisms are shaping testing strategies. They discuss the role of biomarkers, evolving guideline recommendations and how clinicians can adapt testing approaches to align with new targeted therapies. Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Prof. Paul Hofman, University Côte d’Azur, Nice, France.     This touchPODCAST is for HCPs only. This activity is funded by an educational grant from AstraZeneca Ltd.  This medical education is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:   https://touchoncologyime.org/egfr-tki-resistance-strategies-nsclc/ https://touchrespiratoryime.org/egfr-tki-resistance-strategies-nsclc/